Vaxart Inc - Company Profile

Powered by

All the data and insights you need on Vaxart Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Vaxart Inc Strategy Report

  • Understand Vaxart Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Vaxart Inc: Overview

Select Item

Vaxart Inc (Vaxart), formerly Aviragen Therapeutics Inc, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.

 Gain a 360-degree view of Vaxart Inc and make more informed decisions for your business Gain a 360-degree view of Vaxart Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 170 Harbor Way, Suite 300, South San Francisco, California, 94080
Website vaxart.com
Telephone 1 650 5503500
No of Employees 109
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange VXRT (NASD)
Revenue (2022) $7.4M 6796.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 23.5% (2022 vs 2021)
Market Cap* $131.4M
Net Profit Margin (2022) XYZ 98.9% (2022 vs 2021)
* As of and is in US$
View Vaxart Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Vaxart Inc premium industry data and analytics

80+

Clinical Trials

Determine Vaxart Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

80+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Vaxart Inc’s relevant decision makers and contact details.

50+

Pipeline Drugs

Identify which of Vaxart Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Catalyst Calendar

Proactively evaluate Vaxart Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products Brands
Royalty Product: VAAST Platform
Relenza- Influenza
Inavir- Influenza
XYZ
XYZ
XYZ
Understand Vaxart Inc portfolio and identify potential areas for collaboration Understand Vaxart Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Vaxart Inc Moderna Inc Novavax Inc Genexine Inc Inovio Pharmaceuticals Inc
Headquarters United States of America United States of America United States of America South Korea United States of America
City South San Francisco Cambridge Gaithersburg Seoul Plymouth Meeting
State/Province California Massachusetts Maryland - Pennsylvania
No. of Employees 109 5,600 1,543 161 122
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Michael J. Finney, Ph.D. Chairman Executive Board 2023 64
Steven Lo Chief Executive Officer; President; Director Executive Board 2024 -
Phillip Lee Chief Financial Officer Senior Management 2022 -
Raymond D. Stapleton, Jr. Chief Technology Officer Senior Management 2022 -
James F. Cummings Chief Medical Officer Senior Management 2021 57
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Vaxart Inc key executives to enhance your sales strategy Gain insight into Vaxart Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward